After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Celyad today. The company’s shares closed last Monday at $8.00.
According to TipRanks.com, Roy is a 2-star analyst with an average return of -2.4% and a 22.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Monopar Therapeutics Inc, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Celyad with a $40.50 average price target, a 524.0% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $37.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.86 and a one-year low of $4.10. Currently, Celyad has an average volume of 23.33K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
